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Summary.-Overnight exposure of Chinese hamster cells (V79-753B) to 5x 10-5M
flurbiprofen (2-(2-fluoro-4-biphenyl)propionic acid) in vitro reduced the cytotoxic
effects of misonidazole, 1-methyl-4-nitro-5-phenoxysulphonylimidazole (NSC 38087)
and nitrofurantoin, both in air and in hypoxia at 37°C. Flurbiprofen did not alter the
cells' uptake of 14C-misonidazole, nor did it affect the radiosensitivity of aerobic or
anaerobic cells, or the degree of hypoxic-cell radiosensitization produced by the
sensitizers. When flurbiprofen-treated cells were exposed to melphalan there was no
protection against cytotoxicity. These data suggest that flurbiprofen may inhibit the
catabolism of radiosensitizers to toxic products and indicate the need to examine
whether it will protect against misonidazole-induced toxicity in vivo.
CELLS which are depleted of oxygen are
more resistant to the lethal effects of
ionizing radiation than well oxygenated
cells and when present in tumours may
form foci for regrowth after radiotherapy.
Misonidazole (MISO), a 2-nitroimidazole,
has been shown to sensitize hypoxic
mammalian cells selectively to radiation
in vitro (for review see Adams et al., 1978)
and in vivo (Denekamp & Harris, 1975)
and clinical trials are in progress to deter-
mine whether the drug is likely to provide
any therapeutic advantage inradiotherapy
regimes (Dische et al., 1977; Urtason et al.,
1977; Jentzch et al., 1977; Bleehen, 1980).
However, despite the possible advan-
tages of using MISO with radiation treat-
ments for cancer, the use of the drug
clinically is limited because of neuro-
toxicity (Dische et al., 1977) which may be
related to its toxicity to cells in vitro (Hall
& Roizin-Towle, 1975). Nitro-aromatic
compounds such as MISO can be reduced
by some enzymes acting as nitroreduc-
tases, which could lead to the production
oftoxic radical anions, superoxide radicals
and H202 (Biaglow et al., 1977; Mason &
Holtzman, 1975). For example, such
enzyme activity has been proposed to
account for the toxicity of nitrofuran
radiosensitizers in mammalian cells in
vitro (Olive & McCalla, 1975).
There is some evidence that dexa-
methasone, an anti-inflammatory steroid,
protects against MISO-induced neuro-
toxicity in man (Wasserman et al., 1980).
Unfortunately, from experiments in vitro
there is an indication that the radiation
sensitivity of cells is decreased by this
agent (Millar & Jinks, 1981). Thus other
agents are being examined in an attempt
to reduce the toxicity of MISO without
affecting its radiosensitization. This re-
port concerns the effect of a non-steroidal
anti-inflammatory agent, flurbiprofen, on
the radiation response and cytotoxic
effect of radiosensitizers in mammalian
cells in vitro.
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MATERIALS AND METHODS
Compounds.-Misonidazole and 2-14C-mis-
onidazole (53-6 ,tCi/mg) were kindly supplied
by Roche Products (Welwyn Garden City,
Herts). Flurbiprofen sulphate was a generous
gift from the Boots Drug Company (Notting-
ham). Melphalan was obtained from Well-
come Laboratories Ltd (Beckenham, Kent)
and nitrofurantoin from Biorex Laboratories
(London). NSC 38087 (1-methyl-4-nitro-5-
phenoxysulphonylimidazole) was synthesized
in this department by Dr C. Hardy under
Contract No. NOI-CM-77139.
Cell culture.-Chinese hamster cells V79-
753B were used throughout the work. The
routine handling of cells was carried out by
methods described previously (Cooke et al.,
1976).
For experiments involving the pretreat-
mnent of cells with flurbiprofen, 4oz glass
medical flats each containing 6 x 105 cells
were seeded the day before the experiment.
When the cells had attached, the medium was
replaced by similar medium containing
5 x 10-5Mflurbiprofen. The medium on control
cells was replaced at the same time with
fresh medium. On the day of the experiment
cells were trypsinized and harvested as a
single-cell suspension and plated on to 61mm
glass Petri dishes with and without flurbi-
profen, using methods described previously,
and allowed to attach at 37°C (Millar & Jinks,
1981). Flurbiprofen did not affect the doub-
ling time, not did it alter the gross morph-
ology of the cells. In experiments to test the
radiation or cytotoxic response of cells in the
presence of sensitizer or melphalan, flu bi-
profen-treated cultures were exposed to a
mixture of flurbiprofen and the test com-
pound for the duration of the experiment.
Irradiation procedure. For irradiation in
hypoxia, cultures were gassed in sealed
"Dural" containers with 02-free N2 (BOC,
< 10 pts/106) for 15 nin before irradiation.
The irradiation vessels were maintained at
37°C during this time on a temperature-
controlled plate. Irradiation was carried out
at 37°C using a cobalt-60 source and a dose
rate of 4-8 Gy/min. Experimental details
have been reported elsewhere (Millar & Jinks,
1981).
Cytotoxicity.-Cells were seeded and treated
as for irradiation experiments. Anaerobic
toxicity was followed at 37°C, as described
previously (Millar & Jinks, 1981). Aerobic
toxicity was monitored by incubating cul-
tures at 37°C in the presence of the drugs in
an atmosphere of 500 C02/95% air for differ-
ent times.
Colony formation. Cultures were incu-
bated at 37°C in an atmosphere of 500 air/
950/a CO2 for 6 days to allow colony forma-
tion, when the colonies were fixed in ethanol,
stained with methylene blue and counted. All
irradiation data were taken from full survival
curves. Each experiment consisted ofsurvival
curves for cells irradiated as follows: (1) con-
trol hypoxic cells; (2) flurbiprofen-treated
hypoxic cells; (3) untreated hypoxic cells in
the presence of sensitizer; and (4) flurbi-
profen-treated cells in the presence of sensi-
tizer. For experiments where a comparison
between the anaerobic and aerobic survival
was examined Curves 3 and 4 were replaced
by untreated aerobic cells and flurbiprofen-
treated aerobic cells. This allowed the com-
parison of data on a same-day basis. Both
radiation and cytotoxicity experiments were
done at least twice. Diagrams show pooled
data from repeat experiments. Bars indicate
the range ofdata between repeat experiments.
Labelling experiments. The uptake of
2-14C-MISO into flurbiprofen-treated and
control cells was measured by the methods of
Millar & Jinks (1981).
RESULTS
The data in Fig. 1 show the survival of
flurbiprofen-treated and untreated Chinese
hamster cells exposed to 10mM MISO in
air and in hypoxia. Fluribprofen was in
contact with the cells for about 20 h before
and during the experiments. After an 8h
exposure in hypoxia MISO reduced the
survival of flurbiprofen-treated cells to
1 10%, compared with 0.1% for un-
treated cells. Flurbiprofen also protected
against the aerobic cytotoxicity induced
by MISO. After a similar exposure sur-
vival was in excess of60% for flurbiprofen-
treated cells, compared with - 10% for
untreated cells.
Flurbiprofen-treated and untreated cul-
tures were exposed to different concentra-
tions ofMISO for 4 h in air and in hypoxia
to assess a dose-reduction factor against
MISO-induced cytotoxicity. The data in
Fig. 2 show that cells treated with flurbi-
profen were approximately twice as re-
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sistant to MISO toxicity in air or in
hypoxia.
A possible explanation for the reduced
toxicity of MISO in flurbiprofen-treated
cells could be reduced penetration of the
sensitizer. The incorporation of 2-14C-
MISO was measured in untreated and
flurbiprofen-treated cells after a Ih ex-
posure to MISO (Millar & Jinks, 1981).
The uptake of MISO as a percentage of
drug in the medium was 24.5% in un-
treated cells and 29.5% in flurbiprofen-
treated cells. Thus differential uptake
cannot explain the protection against
MISO toxicity.
The radiation response of flurbiprofen-
treated cells showed no significant differ-
ence between their radiosensitivity and
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FIG. 1.-Effect of 5 x 1O-5M flurbiprofen on
the toxicity of 10mM misonidazole in
Chinese hamster cells. (a) Hypoxic cells:
0, flurbiprofen-treated; 0, untreated.
(b) Aerobic cells: 0, flurbiprofen-treated;
0, untreated.
that of untreated cells either in air or in
hypoxia (Fig. 3; OER 3.0), nor was there
any difference in the sensitization pro-
duced by ImM MISO in untreated or
flurbiprofen-treated cells (Fig. 3; ER 1.9).
A second sensitizer, NSC 38087, was
examined which has been shown to be
more toxic to aerobic than hypoxic cells
(Stratford et al., 1981). Fig. 4 shows the
survival of untreated and flurbiprofen-
treated cells exposed to 5,M NSC 38087 in
air and hypoxia. After a 5h hypoxic
exposure there was no appreciable toxicity
in cells pretreated with flurbiprofen,
whereas survival was reduced to about
40% in untreated cultures. After a 3h
exposure in air, cell survival was reduced
to about 25% for flurbiprofen-treated
cells, compared with about 5% for un-
treated cultures.
The hypoxic-cell radiosensitization pro-
duced by 5,M NSC 38087 was not affected
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FIG. 2.-Effect of 5 x 10-5M flurbiprofen on
the toxicity to Chinese hamster cells of a
4h exposure to MISO: 0, untreated cells/
N2; 0, flurbiprofen-treated cells/N2; O,
untreated cells/air; *, flurbiprofen-treated
cells/air.
when the cells were pretreated with
flurbiprofen (ER 2.5).
An alternative explanation for the de-
crease in sensitizer toxicity in cells treated
with flurbiprofen is that the drug inhibits
the catabolism of sensitizers to toxic pro-
ducts. In bacteria McCalla et at. (1971)
have shown that the toxicity ofnitrofuran
radiosensitizers is dependent on the cells
having nitroreductase activity. In view of
this, the toxicity of one such nitrofuran,
nitrofurantoin, was examined in untreated
and flurbiprofen-treated cultures. When
flurbiprofen-treated cells were exposed to
500,uM nitrofurantoin in hypoxia for 3 h,
survival was reduced to 5% compared
with 1.5% for untreated hypoxic cells
exposed to nitrofurantoin for a similar
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FIG. 3. Effect of 5 x 10-5M flurbiprofen on
the radiation survival of Chinese hamster
cells: 0, untreated hypoxic; 0, flurbi-
profen-treated hypoxic; A, untreated aero-
bic; A, flurbiprofen-treated aerobic; L,
untreated hypoxic cells irradiated in the
presence of ImM MISO; *, flurbiprofen-
treated hypoxic cells irradiated in the pre-
sence of lmM MISO.
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FIG. 4.-Effect of5 x 10-5Mflurbiprofen onthe
toxicity of 5/-M NSC 38087 in Chinese
hamster cells: OL, untreated aerobic; *,
flurbiprofen-treated aerobic; 0, untreated
hypoxic; 0, flurbiprofen-treated hypoxic.
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FIG. 6.-Effect of 5 x 10-5M flurbiprofen on
the aerobic toxicity of malphalan in
Chinese hamster cells: 0, untreated;
*, flurbiprofen-treated cells.
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FIG. 5.-Effect of 5 x 10-5M flurbiprofen on
the toxicity of 500,uM nitrofurantoin in
Chinese hamster cells: 0, untreated hyp-
oxic; 0, flurbiprofen-teated hypoxic; 0j,
untreated aerobic; *, flurbiprofen-treated
aerobic.
period (Fig. 5). After a 3h exposure to
nitrofurantoin in aerobic conditions cell
survival was -75% for flurbiprofen-
treated cells compared with 50% for
untreated cells (Fig. 5). Once again, the
amount of hypoxic cell radiosensitization
produced by 500,uM nitrofurantoin was
unaffected when cells were pretreated
with flurbiprofen (ER 1-6).
If the metabolism of sensitizers is
responsible for the cytotoxic effects seen
in vitro, it would be predicted that drugs
which do notrequire activation or metabo-
lism should not show decreased cyto-
toxicity in cells pretreated with flurbi-
profen. The aerobic toxicity of melphalan
was examined in flurbiprofen-treated and
untreated cells after exposure of 1 h to
different concentrations of melphalan.
Pretreatment with flurbiprofen did not
affect the cytotoxicity of melphalan
(Fig. 6).
DISCUSSION
Cells pretreated with flurbiprofen be-
came more resistant to the toxic effects of
radiosensitizers, bothinairandinhypoxia.
This was observed not only with MISO
and nitrofurantoin, which exhibit greater
toxicity towards hypoxic than to aerobic
cells, but also with NSC 38087, which has
been shown to be more toxic in aerobic
conditions (Stratford et al., 1981). Flurbi-
profen did not protect against MISO-
induced toxicity when added to cultures at
the same time as the sensitizer. However,
cultures which had been pretreated with
flurbiprofen were resistant to MISO tox-
icity if the cells were washed free of the
drug immediately before exposure to
MISO. Protection diminished with in-
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creased time between washing cells free of
flurbiprofen and exposure to MISO, and
there was no appreciable protection when
the interval was increased to 3 h. This
suggests that pretreatment induces bio-
chemical changes in vitro which make
cells more resistant to sensitizer toxicity.
Increased resistance was seen predomin-
antly as a change in the shoulder region of
the toxicity curves, and was greater for
MISO than for nitrofurantoin. Since
nitrofurantoin is more electron-affinic than
MISO the data suggest that protection
against sensitizer-induced toxicity in flur-
biprofen-treated cells may depend on elec-
tron affinity. The protection afforded to
flurbiprofen-treated cells was equal to a
dose-reduction factor of2 for the amountof
MISO required to produce a given amount
of cell killing. This protection could not be
explained on the basis of a differential
uptake of MISO into untreated and
flurbiprofen-treated cells, since there was
no significant difference in the incorpora-
tion of2-14C-MISO between untreated and
treated cultures.
Other workers have shown that sulphyd-
ryl (SH) compounds protect against MISO
toxicity in vitro (Taylor & Rauth, 1981)
and that this effect is seen primarily as an
increase in the shoulder of the toxicity
curve. It is unlikely that protection by
flurbiprofen is mediated by an increase in
endogenous SH since such a change would
have affected the response of cells to
radiation. Flurbiprofen did not affect the
radiosensitivity of cells in air or in
hypoxia, whereas addition of SH to cells
before irradiation has been showvn to in-
crease the radiation resistance, the pre-
dominant effect being an increase in the
shoulder of survival curves (Millar et al.,
1980). Furthermore, the lack of change in
radiation sensitivity after treatment with
flurbiprofen contrasts with that previously
reported for cells treated with dexa-
methasone (Millar & Jinks, 1981), which
increased the radioresistance of cells by
25%.
In bacteria it is known that nitrofuran
derivatives such as nitrofurantoin are
activated by flavoproteins (Asnis et al.,
1957) and that mutants resistant to the
toxic effects of these compounds have lost
nitroreductase activity (reductase 1)
(McCalla et al., 1978). Similar reductive
processes have been proposed to account
for their toxicity towards mammalian
cells (Olive & McCalla, 1975). In bacteria,
DNA has been implicated as the target
mainly responsible for cytotoxic (McCalla
et al., 1971, 1978) and mutagenic effects
(Cohen & Bryan, 1973) of these com-
pounds. In mammalian cells exposure to
nitrofurans produces single-strand breaks
in DNA (Olive & McCalla, 1975), though
this has not been shown to be the toxic
event. Varghese & Whitmore (1980) have
suggested nitroreduction and the binding
of nitroreduced products to macromole-
cules as a probable mechanism for the
mutagenic and cytotoxic properties of
MISO. When the toxicity of melphalan
was examined in flurbiprofen-treated cells,
cell killing was similar to that in untreated
cultures. Since melphalan does not require
metabolic activation for tocixity, it is
arguable that flurbiprofen protection
against sensitizer-induced toxicity may be
mediated by the inhibition of events lead-
ing to the production of toxic products.
Flurbiprofen is a potent inhibitor of the
biosynthesis ofprostaglandins from arachi-
donic and linoleic acids released from
phospholipids in the cell membrane.
Prostaglandins are responsible for the
regulation of cyclic nucleotides within
cells (Burstein et al., 1977) and have been
implicated in the release of lysosomal
enzymes; elevated levels of cAMP parallel
the release of f-glucuronidase in vivo after
irradiation (Trocha & Catravas, 1980).
Thus it is possible that flurbiprofen may
inhibit the release of enzymes responsible
for the metabolism ofsensitizers, either by
an effect on prostaglandin biosynthesis
and cAMP levels or by an effect on mem-
brane stability cauised by the accumula-
tion of fatty acids. Alternatively, flurbi-
profen may inhibit specific enzymes simi-
lar to the allopurinol inhibition of
xanthine oxidase in vivo (Raleigh et al.,
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1980). Further experiments are in progress
to investigate these possible mechanisms.
In conclusion, this report indicates that
flurbiprofen, like dexamethasone, reduces
the cytotoxicity of MISO in vitro in air
and in hypoxia, without affecting the
hypoxic-cell radiosensitizing properties of
the compound. However, unlike dexa-
methasone it does not increase the radi-
ation resistance ofcells. This has important
therapeutic implications, because of the
known toxicity ofMISO in vivo. In clinical
studies, dosage with 50 mg of flurbiprofen
3 times daily for 10 days produced a mean
serum concentration of2-43 ,ug/ml, equiva-
lent to 10--5M (Cardoe et al., 1975). Whilst
the concentration of flurbiprofen in this
study was 5 x that attainable clinically,
we have found a similar amount of pro-
tection against MISO toxicity using a con-
centration of only 10-7M flurbiprofen.
Thus it seems probable that concentra-
tions of flurbiprofen which are effective in
vitro are comparable with clinical doses.
We are therefore undertaking toxicity
studies with flurbiprofen and similar
agents with MISO in vivo.
We would like to thank Mr J. Curraint for valuiable
technical assistance and Professor G. E. Adams and
Dr E. Martin Fielden for helpful discussions. The
work was supported by C'RC/MIRC funding.
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